AI speeds adapting to post-COVID 'new normal': WhizAI

With all the challenges the COVID-19 pandemic has added to the life-sciences field's already formidable pile, professionals in the industry are increasingly turning to advanced technology to help keep their R&D work going. One of those technologies of growing interest is artificial intelligence (AI). Outsourcing-Pharma (OSP) recently spoke with Rohit Vashisht (RV), CEO and cofounder of WhizAI, a technology company offering AI solutions specifically targeted toward life-sciences applications, about the technology, and how its use is evolving in the industry. RV: AI means different things to different people. Some believe it is an elixir that will cure everything that's wrong with software and take human productivity to the next level; on the other hand, some think it is all hype and will never work.